Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A

Rhea-AI Filing Summary

Baillie Gifford & Co filed Amendment No. 7 to a Schedule 13G/A reporting its passive ownership in Moderna, Inc. common stock. As of 06/30/2026, Baillie Gifford & Co beneficially owned 18,206,778 shares, representing 4.59% of the outstanding common stock. It reported sole voting power over 17,920,410 shares and sole dispositive power over all 18,206,778 shares, with no shared voting or dispositive power. The filer is identified as an Investment Adviser organized in Scotland, and indicates that it now has ownership of 5 percent or less of this class.

Key Figures

Beneficial ownership: 18,206,778 shares Percent of class: 4.59% Sole voting power: 17,920,410 shares +3 more

6 metrics

Beneficial ownership 18,206,778 shares Common stock of Moderna, Inc. beneficially owned by Baillie Gifford & Co

Percent of class 4.59% Percentage of Moderna common stock class owned as of 06/30/2026

Sole voting power 17,920,410 shares Shares over which Baillie Gifford & Co has sole power to vote

Sole dispositive power 18,206,778 shares Shares over which Baillie Gifford & Co has sole power to dispose

Ownership threshold status 5 percent or less Item 5 indicates ownership of 5 percent or less of a class

Reporting date 06/30/2026 Date as of which the Moderna holdings are reported

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G/A, +1 more

5 terms

beneficially owned financial

"Ownership (a) | Amount beneficially owned: 18,206,778"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 17,920,410"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 18,206,778"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"Moderna, Inc. ... form_type: "SCHEDULE 13G/A""

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Investment Adviser financial

"Investment Adviser Item 4. | Ownership"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 10:10 AM Accepted by SEC EDGAR 07/24/2026 - 10:10 AM Learn about SEC filing dates

FAQ

What stake in Moderna (MRNA) does Baillie Gifford & Co report in this Schedule 13G/A?

Baillie Gifford & Co reports beneficial ownership of 18,206,778 Moderna common shares, representing 4.59% of the class as of June 30, 2026. This reflects a passive institutional holding under Schedule 13G rules.

How much voting power over Moderna (MRNA) shares does Baillie Gifford & Co have?

Baillie Gifford & Co reports sole voting power over 17,920,410 shares of Moderna common stock and no shared voting power. It also reports sole dispositive power over 18,206,778 shares and no shared dispositive power.

Is Baillie Gifford & Co above or below 5% ownership of Moderna (MRNA)?

Baillie Gifford & Co indicates ownership of 4.59% of Moderna’s common stock, which is 5 percent or less of the class. This level is disclosed under Item 5 of the Schedule 13G/A amendment.

What type of filer is Baillie Gifford & Co in relation to Moderna (MRNA)?

Baillie Gifford & Co is identified as an Investment Adviser with its principal business office at 3 Haymarket Square, Edinburgh, EH3 8RY. It files on a Schedule 13G/A basis, reflecting passive institutional ownership.

What is the key date associated with Baillie Gifford & Co’s Moderna (MRNA) holdings in this filing?

The holdings are reported as of 06/30/2026. On that date, Baillie Gifford & Co beneficially owned 18,206,778 shares of Moderna common stock, corresponding to 4.59% of the outstanding class.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

Moderna, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

60770K107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 60770K107

1

Names of Reporting Persons

BAILLIE GIFFORD & CO

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 17,920,410.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 18,206,778.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,206,778.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Moderna, Inc.
(b)	Address of issuer's principal executive offices: 325 BINNEY STREET, 325 BINNEY STREET, CAMBRIDGE, MASSACHUSETTS, 02142.
Item 2.
(a)	Name of person filing: Baillie Gifford & Co
(b)	Address or principal business office or, if none, residence: 3 Haymarket Square, Edinburgh, EH3 8RY
(c)	Citizenship: Scotland
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 60770K107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Investment Adviser
Item 4.	Ownership
(a)	Amount beneficially owned: 18,206,778
(b)	Percent of class: 4.59 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 17,920,410
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 18,206,778
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BAILLIE GIFFORD & CO

Signature:	Grant Meikle
Name/Title:	Regulatory Reporting Manager
Date:	07/24/2026